- Home
- EML vs NOTV Comparison
EML vs NOTV Comparison
Compare EML & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- NOTV
- Stock Information
- Founded
- EML 1858
- NOTV 1974
- Country
- EML United States
- NOTV United States
- Employees
- EML N/A
- NOTV N/A
- Industry
- EML Industrial Machinery/Components
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- NOTV Health Care
- Exchange
- EML Nasdaq
- NOTV Nasdaq
- Market Cap
- EML 130.9M
- NOTV 137.5M
- IPO Year
- EML N/A
- NOTV 1997
- Fundamental
- Price
- EML $22.34
- NOTV $2.04
- Analyst Decision
- EML
- NOTV Strong Buy
- Analyst Count
- EML 0
- NOTV 3
- Target Price
- EML N/A
- NOTV $6.25
- AVG Volume (30 Days)
- EML 14.0K
- NOTV 967.8K
- Earning Date
- EML 05-06-2025
- NOTV 05-07-2025
- Dividend Yield
- EML 1.92%
- NOTV N/A
- EPS Growth
- EML N/A
- NOTV N/A
- EPS
- EML N/A
- NOTV N/A
- Revenue
- EML $271,440,503.00
- NOTV $480,402,000.00
- Revenue This Year
- EML N/A
- NOTV $5.84
- Revenue Next Year
- EML N/A
- NOTV $5.74
- P/E Ratio
- EML $11.17
- NOTV N/A
- Revenue Growth
- EML 8.15
- NOTV N/A
- 52 Week Low
- EML $19.06
- NOTV $1.15
- 52 Week High
- EML $35.03
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- EML 51.50
- NOTV 52.07
- Support Level
- EML $19.06
- NOTV $1.75
- Resistance Level
- EML $23.61
- NOTV $2.36
- Average True Range (ATR)
- EML 0.82
- NOTV 0.17
- MACD
- EML 0.53
- NOTV 0.08
- Stochastic Oscillator
- EML 72.09
- NOTV 74.32
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.